Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

The stock's fall snapped a six-day winning streak.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. If Eli Lilly ...

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...